Spermatogonial Differentiation Via Testicular Organoid
Launched by CELLARTS INC. · Feb 20, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying ways to help men who have difficulty producing sperm, which can lead to infertility. Researchers are exploring if they can create a testicular environment in the lab that supports the growth of sperm cells. They want to understand the genetic factors that contribute to sterility and see if they can use special cells from participants to produce sperm outside the body. This research could offer new insights into treating male infertility.
Men aged 18 to 60 years old who are either fertile or have been diagnosed with infertility are eligible to participate. Those who join will provide blood, skin, and testicular tissue samples as part of routine procedures they are already undergoing for fertility issues. Throughout the study, their safety is a priority, and all procedures will be managed by experienced research staff. This trial is currently recruiting participants, and involvement could help advance understanding of male fertility challenges.
Gender
MALE
Eligibility criteria
- • Inclusion Criteria: Group 1 (Fertile Control)
- • Male sex of reproductive age (between 18 - 60 years old).
- • Evidence of fertility or normal spermatogenesis.
- • Will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes.
- • Inclusion Criteria: Group 2 and 3 (Infertile)
- • Male sex of reproductive age (between 18 - 60 years old).
- • Males with evidence of \>1 year of infertility.
- • Posesses diagnosis of azoospermia is on clinical evaluation.
- • Will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes.
- Exclusion Criteria:
- • - The lack of diagnosis of fertility or infertility, and lack of testicles.
About Cellarts Inc.
CellArts Inc. is a pioneering biotechnology company focused on advancing cell-based therapies and regenerative medicine. With a commitment to innovative research and development, CellArts Inc. leverages cutting-edge technology and expertise to create transformative solutions for a range of medical conditions. The company is dedicated to enhancing patient outcomes through rigorous clinical trials and partnerships with leading academic institutions. By prioritizing safety and efficacy, CellArts Inc. aims to bring novel therapies from the lab to clinical practice, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Paul J Turek, MD
Principal Investigator
Chief Medical Officer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported